NASDAQ:CLVS

Clovis Oncology Competitors

$6.23
-0.35 (-5.32 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.02
Now: $6.23
$6.55
50-Day Range
$5.32
MA: $6.37
$7.86
52-Week Range
$4.08
Now: $6.23
$11.10
Volume5.40 million shs
Average Volume13.34 million shs
Market Capitalization$651.22 million
P/E RatioN/A
Dividend YieldN/A
Beta2.1

Competitors

Clovis Oncology (NASDAQ:CLVS) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying CLVS stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Clovis Oncology, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Clovis Oncology (NASDAQ:CLVS) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of current ratings for Clovis Oncology and Amgen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Clovis Oncology22202.00
Amgen0101402.58

Clovis Oncology presently has a consensus price target of $9.50, suggesting a potential upside of 52.49%. Amgen has a consensus price target of $259.4091, suggesting a potential upside of 4.20%. Given Clovis Oncology's higher possible upside, research analysts clearly believe Clovis Oncology is more favorable than Amgen.

Profitability

This table compares Clovis Oncology and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Clovis Oncology-230.34%N/A-57.56%
Amgen29.42%95.55%15.52%

Institutional & Insider Ownership

57.8% of Clovis Oncology shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 6.6% of Clovis Oncology shares are owned by company insiders. Comparatively, 0.4% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Clovis Oncology and Amgen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clovis Oncology$143.01 million4.55$-400,420,000.00($7.60)-0.82
Amgen$23.36 billion6.14$7.84 billion$14.8216.80

Amgen has higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Clovis Oncology has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Summary

Amgen beats Clovis Oncology on 11 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Clovis Oncology (NASDAQ:CLVS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Volatility and Risk

Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Gilead Sciences and Clovis Oncology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences191402.54
Clovis Oncology22202.00

Gilead Sciences currently has a consensus price target of $97.2308, suggesting a potential upside of 49.33%. Clovis Oncology has a consensus price target of $9.50, suggesting a potential upside of 52.49%. Given Clovis Oncology's higher possible upside, analysts plainly believe Clovis Oncology is more favorable than Gilead Sciences.

Institutional and Insider Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 6.6% of Clovis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Gilead Sciences and Clovis Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Clovis Oncology-230.34%N/A-57.56%

Earnings & Valuation

This table compares Gilead Sciences and Clovis Oncology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.65$5.39 billion$6.1410.60
Clovis Oncology$143.01 million4.55$-400,420,000.00($7.60)-0.82

Gilead Sciences has higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Clovis Oncology on 10 of the 14 factors compared between the two stocks.

Clovis Oncology (NASDAQ:CLVS) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Earnings & Valuation

This table compares Clovis Oncology and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clovis Oncology$143.01 million4.55$-400,420,000.00($7.60)-0.82
Vertex Pharmaceuticals$4.16 billion13.32$1.18 billion$4.2949.73

Vertex Pharmaceuticals has higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Clovis Oncology and Vertex Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Clovis Oncology22202.00
Vertex Pharmaceuticals042112.88

Clovis Oncology presently has a consensus target price of $9.50, suggesting a potential upside of 52.49%. Vertex Pharmaceuticals has a consensus target price of $293.1250, suggesting a potential upside of 37.39%. Given Clovis Oncology's higher probable upside, equities analysts clearly believe Clovis Oncology is more favorable than Vertex Pharmaceuticals.

Volatility and Risk

Clovis Oncology has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares Clovis Oncology and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Clovis Oncology-230.34%N/A-57.56%
Vertex Pharmaceuticals38.51%28.55%20.68%

Institutional & Insider Ownership

57.8% of Clovis Oncology shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 6.6% of Clovis Oncology shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Clovis Oncology on 12 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Clovis Oncology (NASDAQ:CLVS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Profitability

This table compares Regeneron Pharmaceuticals and Clovis Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Clovis Oncology-230.34%N/A-57.56%

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Clovis Oncology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.47$2.12 billion$21.4722.13
Clovis Oncology$143.01 million4.55$-400,420,000.00($7.60)-0.82

Regeneron Pharmaceuticals has higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 6.6% of Clovis Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Regeneron Pharmaceuticals and Clovis Oncology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Clovis Oncology22202.00

Regeneron Pharmaceuticals presently has a consensus price target of $637.2083, suggesting a potential upside of 34.10%. Clovis Oncology has a consensus price target of $9.50, suggesting a potential upside of 52.49%. Given Clovis Oncology's higher probable upside, analysts plainly believe Clovis Oncology is more favorable than Regeneron Pharmaceuticals.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Clovis Oncology on 13 of the 15 factors compared between the two stocks.

Clovis Oncology (NASDAQ:CLVS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Volatility and Risk

Clovis Oncology has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Clovis Oncology and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Clovis Oncology22202.00
Biogen5141202.23

Clovis Oncology currently has a consensus target price of $9.50, suggesting a potential upside of 52.49%. Biogen has a consensus target price of $303.5517, suggesting a potential upside of 13.19%. Given Clovis Oncology's higher probable upside, equities analysts plainly believe Clovis Oncology is more favorable than Biogen.

Insider & Institutional Ownership

57.8% of Clovis Oncology shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 6.6% of Clovis Oncology shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Clovis Oncology and Biogen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clovis Oncology$143.01 million4.55$-400,420,000.00($7.60)-0.82
Biogen$14.38 billion2.84$5.89 billion$33.577.99

Biogen has higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Clovis Oncology and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Clovis Oncology-230.34%N/A-57.56%
Biogen35.63%51.00%23.54%

Summary

Biogen beats Clovis Oncology on 10 of the 14 factors compared between the two stocks.

Clovis Oncology (NASDAQ:CLVS) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Clovis Oncology and Alexion Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Clovis Oncology22202.00
Alexion Pharmaceuticals017512.30

Clovis Oncology presently has a consensus price target of $9.50, indicating a potential upside of 52.49%. Alexion Pharmaceuticals has a consensus price target of $153.8636, indicating a potential downside of 0.74%. Given Clovis Oncology's higher probable upside, equities analysts clearly believe Clovis Oncology is more favorable than Alexion Pharmaceuticals.

Earnings & Valuation

This table compares Clovis Oncology and Alexion Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clovis Oncology$143.01 million4.55$-400,420,000.00($7.60)-0.82
Alexion Pharmaceuticals$4.99 billion6.83$2.40 billion$9.7415.91

Alexion Pharmaceuticals has higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

57.8% of Clovis Oncology shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 6.6% of Clovis Oncology shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Clovis Oncology and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Clovis Oncology-230.34%N/A-57.56%
Alexion Pharmaceuticals16.32%23.16%14.76%

Risk and Volatility

Clovis Oncology has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Clovis Oncology on 12 of the 15 factors compared between the two stocks.

pixel
Ad True Market Insiders
Insider Urges: Get Out Of Cash Before April 27th
Chris Rowe says there’s a huge stock market event looming - and he’s revealing his #1 pick for free.

Clovis Oncology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$248.95-0.8%$143.35 billion$23.36 billion20.08Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$65.11-0.1%$81.98 billion$22.45 billion67.12
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$213.35-1.4%$55.46 billion$4.16 billion26.94Insider Selling
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$475.17-0.3%$50.91 billion$7.86 billion17.37News Coverage
Biogen logo
BIIB
Biogen
1.9$268.17-0.9%$40.85 billion$14.38 billion8.88
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$155.01-0.3%$34.08 billion$4.99 billion36.22
Seagen logo
SGEN
Seagen
1.7$142.85-1.1%$25.90 billion$916.71 million56.24Insider Selling
News Coverage
Exact Sciences logo
EXAS
Exact Sciences
1.8$125.54-2.4%$21.23 billion$876.29 million-56.81Gap Down
Incyte logo
INCY
Incyte
1.9$79.96-1.1%$17.58 billion$2.16 billion-50.93News Coverage
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.23-3.1%$16.22 billion$219.75 million-17.65News Coverage
Gap Down
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$77.07-1.5%$14.01 billion$1.70 billion17.64Insider Selling
News Coverage
Novavax logo
NVAX
Novavax
1.6$179.74-1.9%$13.28 billion$18.66 million-34.43Insider Selling
Gap Up
Repligen logo
RGEN
Repligen
1.5$206.10-0.9%$11.29 billion$270.24 million251.34News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.36-1.3%$9.06 billion$1.45 billion19.24Analyst Report
Analyst Revision
News Coverage
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.35-0.7%$8.77 billion$788.10 million100.38Analyst Downgrade
Exelixis logo
EXEL
Exelixis
1.9$23.12-1.0%$7.21 billion$967.78 million48.17
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.77-1.3%$6.13 billion$195.99 million267.31
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.36-0.8%$5.97 billion$1.12 billion88.25
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$28.16-1.1%$2.12 billion$638.60 million-10.83
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$10.21-1.9%$1.81 billion$48.83 million-13.43
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.02-2.1%$1.58 billion$102.43 million-18.37Analyst Upgrade
Gap Down
Codexis logo
CDXS
Codexis
1.1$24.00-2.6%$1.55 billion$68.46 million-68.57Insider Selling
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
Gap Down
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-1.0%$1.14 billion$35.22 million-7.35
Curis logo
CRIS
Curis
1.3$11.50-2.9%$1.05 billion$10 million-14.02Gap Down
MannKind logo
MNKD
MannKind
1.4$4.24-1.9%$1.05 billion$63.04 million-20.19News Coverage
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25-2.2%$891.85 million$227.19 million45.14Analyst Upgrade
Gap Down
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19-2.0%$842.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$20.71-1.4%$820.43 million$3.57 million-9.29Analyst Upgrade
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37-1.1%$775.18 million$322.07 million-5.11
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17-5.3%$731.97 million$252 million-2.27Gap Down
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32-2.1%$714.48 million$150,000.00-4.74Gap Down
Agenus logo
AGEN
Agenus
1.6$2.79-0.0%$570.05 million$150.05 million-2.56
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26-1.8%$554.59 million$59.29 million-21.73
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.44-10.3%$516.29 million$36.63 million-6.40Analyst Downgrade
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Verastem logo
VSTM
Verastem
1.1$2.76-1.8%$473.80 million$17.46 million-1.96Analyst Report
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.07-3.9%$471.95 million$109.33 million-2.26Gap Down
Geron logo
GERN
Geron
1.4$1.48-2.7%$471.43 million$460,000.00-4.23Analyst Report
News Coverage
Gap Down
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.23-0.4%$461.31 million$22.27 million-4.03Analyst Report
Insider Buying
High Trading Volume
Unusual Options Activity
Analyst Revision
XOMA logo
XOMA
XOMA
1.3$38.99-0.8%$438.75 million$18.37 million-35.13Analyst Upgrade
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.